Observations placeholder
Januvia
Identifier
019228
Type of Spiritual Experience
Background
A description of the experience
Sitagliptin , previously identified as MK-0431 and marketed as the phosphate salt under the trade name Januvia) is an oral antihyperglycemic (antidiabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The claim for this medicine is its fewer side effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. ....., efficacy is often challenged as it is often recommended to be combined with other agents such as metformin.
There have been several postmarketing reports of pancreatitis (some fatal) in people treated with sitagliptin and other DPP-4 inhibitors and the U.S. package insert carries a warning to this effect, ... They may cause severe joint pain.
The existence of case reports of renal failure and hypersensitivity reactions is noted in the United States prescribing information.
On Dec, 19, 2016 37,806 people reported to have side effects when taking Januvia.
Among them, 98 people (0.26%) have Hallucination
Time on Januvia when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 83.33% | 16.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Jan, 2, 2016: 19,187 people reported to have side effects when taking Januvia. Among them, 280 people (1.46%) have Death.
Time on Januvia when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 40.00% | 47.14% | 2.86% | 7.14% | 2.86% | 0.00% | 0.00% |